Eugene A. Zhukovsky

Glenmark Pharmaceuticals (India) — India

Medicine · Health Sciences

22h-index2.9kcitations75works14.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(57), CAR-T cell therapy research(29), Glycosylation and Glycoproteins Research(18), Lymphoma Diagnosis and Treatment(12), Immune Cell Function and Interaction(9)

Publications75 total

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
mAbs·2025Open Access
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Nature Cancer·2024· 29 citedOpen Access
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Frontiers in Immunology·2023· 6 citedOpen Access
Abstract 2954: MAIT engagers: An efficacious novel modality in the field of T-cell engagers for the treatment of solid tumors
Cancer Research·2023
Supplementary Figure 1 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Data from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Supplementary Figure 2 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Supplementary Figure 3 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Data from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Supplementary Figure 3 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Supplementary Figure 1 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Supplementary Figure 2 from Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2023Open Access
Supplementary Figure Legends 1-3 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Supplementary Figure Legends 1-3 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Supplementary Figure 2 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Supplementary Figure 3 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Supplementary Figure 1 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Supplementary Figure 1 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Data from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
Supplementary Figure 2 from Potent <i>In vitro</i> and <i>In vivo</i> Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Uwe Reusch(20), Ivica Fucek(17), Stefan Knackmuss(17), Seung Y. Chu(13), John R. Desjarlais(13), Kristina Ellwanger(13), Sher Karki(10), Carmen Burkhardt(10), Matthew J. Bernett(8), Matthias Peipp(8), Roland Repp(8), Melvyn Little(8), Markus Eser(8), Holly M. Horton(7), Erik Pong(7), John O. Richards(7), Fionnuala McAleese(6), Michael Weichel(6), Erich Rajkovic(5), Daniel D. Oprian(4)